Robotic surgery for esophageal cancer: a gentler approach?
NCT ID NCT04938973
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial compared a newer, robotic-assisted minimally invasive surgery (RAMIE) to the standard open surgery for esophageal cancer. The goal was to see if it's possible to run a larger study comparing the two approaches. The study enrolled 24 adults with stage I-III esophageal cancer. The robotic approach aims to reduce the high complication rates and long recovery times associated with open surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Robotic-assisted minimally invasive esophagectomy (RAMIE) using the Da Vinci robotic platform
- What this could lead to
- If successful, this approach could offer a less invasive surgical option for esophageal cancer, potentially reducing recovery time and complications compared to open surgery.
- What could go wrong
- This was a small feasibility trial that was terminated early, so results are limited. Robotic surgery is complex and may not be suitable for all patients, and its benefits over open surgery are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
24 people
The number who actually took part.
- Started
-
May 2022
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 or older * Clinical Stage I, II, or III esophageal cancer, who are candidates for surgery after discussion in multidisciplinary tumor board. * Candidates for minimally invasive surgery as determined by the operating surgeon. Exclusion Criteria: * Hypersensitivity or allergy to ICG, sodium iodide, or iodine * Women who are currently pregnant or are breastfeeding; or women of childbearing potential who are not currently taking adequate birth control * Clinical Stage IV esophageal cancer. * Not a candidate for minimally invasive surgery as determined by the operating surgeon.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N4A6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?
- Can a new drug shrink tumors that resist standard care?